Evidence map›Paper›PMID 41702512›Full record

ArticleJournal of controlled release : official journal of the Controlled Release Society2026

A multidomain peptide hydrogel-liposome composite for controlled release of a cyclic dinucleotide in oral cancer.

Joseph W R Swain, Andrea H Molina, Gemalene M Sunga, Danielle Chew-Martinez, Neeraja Dharmaraj, Alejandra Cobos Perez, Arghadip Dey, Ephraim J Vázquez-Rosado, Simon Young, Jeffrey D Hartgerink

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of controlled release : official journal of the Controlled Release Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Joseph W R SwainDepartment of Chemistry, Rice University, 6100 Main Street, Houston, TX 77098, USA.
Andrea H MolinaKatz Department of Oral and Maxillofacial Surgery, The University of Texas Health Science Center at Houston School of Dentistry, 7500 Cambridge Street, Houston, TX 77054, USA.
Gemalene M SungaKatz Department of Oral and Maxillofacial Surgery, The University of Texas Health Science Center at Houston School of Dentistry, 7500 Cambridge Street, Houston, TX 77054, USA; Department of Head and Neck Surgery, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, United States.
Danielle Chew-MartinezDepartment of Chemistry, Rice University, 6100 Main Street, Houston, TX 77098, USA.
Neeraja DharmarajKatz Department of Oral and Maxillofacial Surgery, The University of Texas Health Science Center at Houston School of Dentistry, 7500 Cambridge Street, Houston, TX 77054, USA.
Alejandra Cobos PerezKatz Department of Oral and Maxillofacial Surgery, The University of Texas Health Science Center at Houston School of Dentistry, 7500 Cambridge Street, Houston, TX 77054, USA; Department of Bioengineering, Rice University, 6100 Main Street, Houston, TX 77098, USA.
Arghadip DeyDepartment of Chemistry, Rice University, 6100 Main Street, Houston, TX 77098, USA.
Ephraim J Vázquez-RosadoKatz Department of Oral and Maxillofacial Surgery, The University of Texas Health Science Center at Houston School of Dentistry, 7500 Cambridge Street, Houston, TX 77054, USA; Department of Diagnostic and Biomedical Sciences, The University of Texas Health Science Center at Houston School of Dentistry, 7500 Cambridge Street, Houston, TX 77054, USA.
Simon YoungKatz Department of Oral and Maxillofacial Surgery, The University of Texas Health Science Center at Houston School of Dentistry, 7500 Cambridge Street, Houston, TX 77054, USA.
Jeffrey D HartgerinkDepartment of Chemistry, Rice University, 6100 Main Street, Houston, TX 77098, USA; Department of Bioengineering, Rice University, 6100 Main Street, Houston, TX 77098, USA. Electronic address: jdh@rice.edu.

Funding

SynerGel: A Novel Tumor Microenvironment-Modulating Hydrogel for Local ImmunotherapyR01DE030140 · NIDCR · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI YOUNG, SIMON · 2021 to 2025
$3.0M
NIDCR NIH HHS R01 DE030140
6 · The paper itself

Abstract

While immunotherapy is a promising treatment strategy for cancer, the majority of head and neck squamous cell carcinoma (HNSCC) patients treated with single-agent immunotherapy do not respond. Therefore, researchers are investigating combination treatments with immunostimulatory molecules that can maximize anti-tumor responses. Cyclic dinucleotides (CDNs) are STING agonists that hold promise in combination approaches, but they require frequent intratumoral administration when used in both preclinical models of HNSCC and clinical trials. To reduce administration frequency, we have created a peptide hydrogel-liposome composite system, K

Indexed as

Antineoplastic AgentsHydrogelsMouth NeoplasmsPeptidesAnimalsCell Line, TumorDelayed-Action PreparationsFemaleHumansLiposomesMiceAntineoplastic AgentsDelayed-Action PreparationsHydrogelsLiposomesPeptidesImmunotherapyLiposomeOral cancerPeptideSelf-assembly

Identifiers

PMID41702512
PMCPMC13005698

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.